Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions

Open access
van Dessel, Lisanne F., Beije, Nick, Helmijr, Jean C.A., Vitale, Silvia R., Kraan, Jaco, Look, Maxime P., de Wit, Ronald, Sleijfer, Stefan, Jansen, Maurice P.H.M., Martens, John W.M., Lolkema, Martijn P. · 2017 · Molecular Oncology

Abstract

Circulating tumor DNA (ct DNA) has emerged as a potential new biomarker with diagnostic, predictive, and prognostic applications for various solid tumor types. Before beginning large prospective clinical trials to prove the added value of utilizing ct DNA in clinical practice, it is essential to investigate the effects of various preanalytical conditions on the quality of cell‐free DNA (cf DNA) in general and of ct DNA in particular in order to optimize and standardize these conditions. Whole blood samples were collected from patients with metastatic cancer bearing a known somatic variant. The following preanalytical conditions were investigated: (a) different time intervals to plasma isolation (1, 24, and 96 h) and (b) different preservatives in blood collection tubes (EDTA, CellSave, and BCT). The quality of cf DNA/ct DNA was assessed by DNA quantification, digital polymerase chain reaction (dPCR) for somatic variant detection and a β‐actin fragmentation assay for DNA contamination from lysed leukocytes. In 11 (69%) of our 16 patients, we were able to detect the known somatic variant in ct DNA. We observed a time‐dependent increase in cf DNA concentrations in EDTA tubes, which was positively correlated with an increase in wild‐type copy numbers and large DNA fragments (> 420 bp). Using different preservatives did not affect somatic variant detection ability, but did stabilize cf DNA concentrations over time. Variant allele frequency was affected by fluctuations in cf DNA concentration only in EDTA tubes at 96 h. Both CellSave and BCT tubes ensured optimal ct DNA quality in plasma processed within 96 h after blood collection for downstream somatic variant detection by dPCR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.12037

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 162

Metadata

Authors
van Dessel, L. F., Beije, N., Helmijr, J. C. A., Vitale, S. R., Kraan, J., Look, M. P., de Wit, R., Sleijfer, S., Jansen, M. P. H. M., Martens, J. W. M., & Lolkema, M. P.
Venue
Molecular Oncology
Publisher
Wiley
Published
2017-02-22
Volume
11
Issue
3
Pages
295-304
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2586174920
Cited by
162
References
4
FWCI
6.30
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions. https://app.cochat.ai/papers/10.1002/1878-0261.12037
The paper
van Dessel, L. F., Beije, N., Helmijr, J. C. A., Vitale, S. R., Kraan, J., Look, M. P., de Wit, R., Sleijfer, S., Jansen, M. P. H. M., Martens, J. W. M., & Lolkema, M. P. (2017). Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions. Molecular Oncology. https://doi.org/10.1002/1878-0261.12037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.